Clinical trials based on the administration of SMO antagonists have demonstrated effectiveness in HH-driven tumors, such as BCC and medulloblastoma; however, the therapeutic efficacy of SMO inhibitors may not be effective in tumors having non-canonical activation of GLI1. Here, GLI1 is linked to medulloblastoma.